Triflumidate is a fluoroalkanesulfonanilide. It had been identified for clinical trials. This non-steroidal compound is an anti-inflammatory agent.

Probarbital is ethylisopropylbarbituric acid patented by Thorp, L as hypnotic and sedative agent.

Toquizine is an anticholinergic agent. It was used as an antiulcer agent.

Cyproquinate is an anticoccidial drug, discovered by CIBA in the 1970s. Cyproquinate demonstrated marked anticoccidial activity against E. tenella infected chicks, and against a mixed coccidial infection. Cyproquinate also possessed antimalarial activity, as was demonstrated in a Novartis screen for antimalarial compounds.

Etoprine, a diaminopyrimidine, is a lipid-soluble inhibitor of dihydrofolate reductase. Etoprine inhibits incorporation of deoxyuridine into the DNA. In male rodents, it affected spermatogenesis and induces infertility. Etoprine is considered to exert antineoplastic activity.

Amonafide L-malate (AS1413, Xanafide) is a DNA intercalator and topoisomerase II inhibitor that induces apoptosis by disrupting chromatin organisation independently of ATP. This is different from classical topoisomerase II inhibitors which induce apoptosis by causing extensive DNA damage. Amonafide L-malate is also able to evade P-glycoprotein and related transporters that contribute to multi-drug resistance. AS1413 had orphan drug status in both the U.S. and the E.U. for the treatment of AML and also received Fast Track status from the U.S. FDA for the treatment of secondary AML. Amonafide L-malate was originated by Xanthus Pharmaceuticals. It was added to Antisoma's pipeline through the acquisition of Xanthus Pharmaceuticals, Inc. in June 2008. Antisoma discontinued development of Amonafide L-malate after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine missed the primary endpoint of significantly improving initial remission rate, defined as the proportion of patients who achieve CR or CRi, vs. daunorubicin plus cytarabine.

Piroximone is a nonglycoside, noncatecholamine inotropic agent. In animal experiments, it has been shown to increase cardiac contractility by mechanisms unrelated to any known receptor, acting mainly by inhibition of type III phosphodiesterase. Piroximone also possesses direct vasodilatory properties in the arterial and venous vascular bed. Piroximone combines well-balanced vasodilator and inotropic properties which make it very useful for the management of congestive heart failure. Piroximone had been in phase II clinical trial for the treatment of heart failure. However, this research has been discontinued.

Guanacline was studied in the treatment of hypertension. However, information about the current use of this compound is not available.

Oxmetidine is an H2-receptor antagonist that was studied as a gastrointestinal agent. Oxmetidine possesses efficacy in the treatment of peptic ulcers. However, information about the further development of this drug is not available.